Skip to main content
Top
Gepubliceerd in: Huisarts en wetenschap 11/2011

01-11-2011 | Onderzoek

Zorg aan borstkankerpatiënten tijdens de behandeling

Auteurs: ir. C. Roorda-Lukkien, dr. W.J. van der Veen, A. Lindeman, prof.dr. K. van der Meer, prof.dr. G.H. de Bock, dr. L. Jansen

Gepubliceerd in: Huisarts en wetenschap | Uitgave 11/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

 

Roorda C, De Bock GH, Van der Veen WJ, Lindeman A, Jansen L, Van der Meer K. Zorg aan borstkankerpatiënten tijdens de behandeling. Huisarts Wet 2011;54(11):598-601.

Achtergrond

Huisartsen kunnen een belangrijke rol spelen in de gecoördineerde oncologische zorg aan borstkankerpatiënten. Er is echter weinig onderzoek gedaan naar hun rol tijdens de behandelfase. Wij onderzochten welk beroep vrouwen met borstkanker doen op hun huisarts, en vergeleken hun zorggebruik met dat van vrouwen zonder borstkanker.

Methode

Uit de database van het Registratie Netwerk Groningen selecteerden wij 185 patiënten die tussen 1998 en 2007 een eerste diagnose borstkanker kregen, en wij matchten hen met 548 vrouwen zonder borstkanker uit dezelfde populatie. Beide groepen waren vergelijkbaar qua geboortejaar en huisarts.

Resultaten

De borstkankerpatiënten hadden in het jaar volgend op de diagnose tweemaal zo vaak contact met hun huisartsenpraktijk als vrouwen zonder borstkanker (mediaan 6,0 versus 3,0 consulten en visites, p < 0,001), en zij kregen ruim anderhalf keer zo vaak een recept (11,0 versus 7,0 medicatievoorschriften, p < 0,001). Daarbij ging het veelal om aan de borstkanker gerelateerde klachten, zoals maagdarmproblemen, psychische klachten en om hormoontherapie.

Conclusie

Huisartsen leveren een actieve bijdrage aan de behandeling van borstkanker, met name waar het gaat om de bestrijding van bijwerkingen en om hormoontherapie.
Literatuur
1.
go back to reference Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167–80.PubMedCrossRef Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167–80.PubMedCrossRef
2.
go back to reference Montazeri A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32.PubMedCrossRef Montazeri A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32.PubMedCrossRef
3.
go back to reference Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156–66.PubMedCrossRef Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010;73:156–66.PubMedCrossRef
4.
go back to reference Campbell NC, Macleod U, Weller D. Primary care oncology: Essential if high quality cancer care is to be achieved for all. Fam Pract 2002;19:577–8.PubMedCrossRef Campbell NC, Macleod U, Weller D. Primary care oncology: Essential if high quality cancer care is to be achieved for all. Fam Pract 2002;19:577–8.PubMedCrossRef
5.
go back to reference McAvoy BR. General practitioners and cancer control. Med J Aust 2007;187:115–7.PubMed McAvoy BR. General practitioners and cancer control. Med J Aust 2007;187:115–7.PubMed
6.
go back to reference Weller DP, Harris MF. Cancer care: What role for the general practitioner? Med J Aust 2008;189:59–60.PubMed Weller DP, Harris MF. Cancer care: What role for the general practitioner? Med J Aust 2008;189:59–60.PubMed
7.
go back to reference Pascoe SW, Neal RD, Allgar VL, Selby PJ, Wright EP. Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract 2004;21:437–42.PubMedCrossRef Pascoe SW, Neal RD, Allgar VL, Selby PJ, Wright EP. Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract 2004;21:437–42.PubMedCrossRef
8.
go back to reference Grunfeld E, Earle CC. The interface between primary and oncology specialty care: Treatment through survivorship. J Natl Cancer Inst Monogr 2010;2010:25–30.PubMedCrossRef Grunfeld E, Earle CC. The interface between primary and oncology specialty care: Treatment through survivorship. J Natl Cancer Inst Monogr 2010;2010:25–30.PubMedCrossRef
9.
go back to reference Macleod U, Ross S, Twelves C, George WD, Gillis C, Watt GC. Primary and secondary care management of women with early breast cancer from affluent and deprived areas: Retrospective review of hospital and general practice records. BMJ 2000;320:1442–5.PubMedCrossRef Macleod U, Ross S, Twelves C, George WD, Gillis C, Watt GC. Primary and secondary care management of women with early breast cancer from affluent and deprived areas: Retrospective review of hospital and general practice records. BMJ 2000;320:1442–5.PubMedCrossRef
10.
go back to reference Del Giudice L, Bondy SJ, Chen Z, Maaten S. Physician care of cancer patients. In: Jaakkimainen L, Upshur R, Klein-Geltink JE, Leong A, Maaten S, Schultz SE, et al, editors. Primary care in Ontario: ICES Atlas. Toronto: Institute for Clinical Evaluative Sciences, 2006. Del Giudice L, Bondy SJ, Chen Z, Maaten S. Physician care of cancer patients. In: Jaakkimainen L, Upshur R, Klein-Geltink JE, Leong A, Maaten S, Schultz SE, et al, editors. Primary care in Ontario: ICES Atlas. Toronto: Institute for Clinical Evaluative Sciences, 2006.
11.
go back to reference Roorda C, De Bock GH, Van der Veen WJ, Lindeman A, Jansen L, Van der Meer K. Role of the general practitioner during the active breast cancer treatment phase: An analysis of health care use. Support Care Cancer 2011 Mar 25. Roorda C, De Bock GH, Van der Veen WJ, Lindeman A, Jansen L, Van der Meer K. Role of the general practitioner during the active breast cancer treatment phase: An analysis of health care use. Support Care Cancer 2011 Mar 25.
12.
go back to reference Tate AR, Martin AG, Murray-Thomas T, Anderson SR, Cassell JA. Determining the date of diagnosis–is it a simple matter? The impact of different approaches to dating diagnosis on estimates of delayed care for ovarian cancer in UK primary care. BMC Med Res Methodol 2009;9:42.PubMedCrossRef Tate AR, Martin AG, Murray-Thomas T, Anderson SR, Cassell JA. Determining the date of diagnosis–is it a simple matter? The impact of different approaches to dating diagnosis on estimates of delayed care for ovarian cancer in UK primary care. BMC Med Res Methodol 2009;9:42.PubMedCrossRef
13.
go back to reference Lawrenson R, Williams T, Farmer R. Clinical information for research: The use of general practice databases. J Public Health Med 1999;21:299–304.PubMedCrossRef Lawrenson R, Williams T, Farmer R. Clinical information for research: The use of general practice databases. J Public Health Med 1999;21:299–304.PubMedCrossRef
14.
go back to reference Pascoe SW, Neal RD, Heywood PL, Allgar VL, Miles JN, Stefoski-Mikeljevic J. Identifying patients with a cancer diagnosis using general practice medical records and Cancer Registry data. Fam Pract 2008;25:215–20.PubMedCrossRef Pascoe SW, Neal RD, Heywood PL, Allgar VL, Miles JN, Stefoski-Mikeljevic J. Identifying patients with a cancer diagnosis using general practice medical records and Cancer Registry data. Fam Pract 2008;25:215–20.PubMedCrossRef
15.
go back to reference Van der Veen WJ, Meyboom-de Jong B. Age and gender. In: Jones R, Britten N, Culpepper L, Gass D, Grol R, Mant D, et al, editors. Oxford textbook of primary medical care. Oxford (UK): Oxford University Press, 2004. Van der Veen WJ, Meyboom-de Jong B. Age and gender. In: Jones R, Britten N, Culpepper L, Gass D, Grol R, Mant D, et al, editors. Oxford textbook of primary medical care. Oxford (UK): Oxford University Press, 2004.
16.
go back to reference Hawfield A, Lovato J, Covington D, Kimmick G. Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol 2006;59:250–5.PubMedCrossRef Hawfield A, Lovato J, Covington D, Kimmick G. Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. Crit Rev Oncol Hematol 2006;59:250–5.PubMedCrossRef
17.
go back to reference Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549–55.PubMedCrossRef Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549–55.PubMedCrossRef
18.
go back to reference Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: Patient knowledge, beliefs, and medical mistrust. J Clin Oncol 2009;27:5160–7.PubMedCrossRef Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: Patient knowledge, beliefs, and medical mistrust. J Clin Oncol 2009;27:5160–7.PubMedCrossRef
19.
go back to reference Garg P, Rana F, Gupta R, Buzaianu EM, Guthrie TH. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Breast J 2009;15:404–8.PubMedCrossRef Garg P, Rana F, Gupta R, Buzaianu EM, Guthrie TH. Predictors of toxicity and toxicity profile of adjuvant chemotherapy in elderly breast cancer patients. Breast J 2009;15:404–8.PubMedCrossRef
20.
go back to reference Van Herk-Sukel MP, Van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis. Breast Cancer Res Treat 2010;122:843–51.PubMedCrossRef Van Herk-Sukel MP, Van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GA, Coebergh JW, Herings RM. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis. Breast Cancer Res Treat 2010;122:843–51.PubMedCrossRef
21.
go back to reference Grunfeld E. Primary care physicians and oncologists are players on the same team. J Clin Oncol 2008;26:2246–7.PubMedCrossRef Grunfeld E. Primary care physicians and oncologists are players on the same team. J Clin Oncol 2008;26:2246–7.PubMedCrossRef
22.
go back to reference Jefford M, Baravelli C, Dudgeon P, Dabscheck A, Evans M, Moloney M, et al. Tailored chemotherapy information faxed to general practitioners improves confidence in managing adverse effects and satisfaction with shared care: Results from a randomized controlled trial. J Clin Oncol 2008;26:2272–7.PubMedCrossRef Jefford M, Baravelli C, Dudgeon P, Dabscheck A, Evans M, Moloney M, et al. Tailored chemotherapy information faxed to general practitioners improves confidence in managing adverse effects and satisfaction with shared care: Results from a randomized controlled trial. J Clin Oncol 2008;26:2272–7.PubMedCrossRef
Metagegevens
Titel
Zorg aan borstkankerpatiënten tijdens de behandeling
Auteurs
ir. C. Roorda-Lukkien
dr. W.J. van der Veen
A. Lindeman
prof.dr. K. van der Meer
prof.dr. G.H. de Bock
dr. L. Jansen
Publicatiedatum
01-11-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 11/2011
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/s12445-011-0291-9

Andere artikelen Uitgave 11/2011

Huisarts en wetenschap 11/2011 Naar de uitgave